Stock RLYB RALLYBIO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
1.58 USD +1.28% Intraday chart for Rallybio Corporation -0.63% -33.89%
May. 15 JPMorgan Downgrades Rallybio to Neutral From Overweight MT
May. 09 Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Rallybio : The Citizens JMP Life Sciences Conference
PU
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
BU
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
BU
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB
AQ
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
BU
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
BU
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
BU
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
BU
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
BU
Rallybio : RLYB116 Conference Call
PU
Rallybio : RLYB116 Presentation
PU
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
BU
Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116
AQ
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
AQ
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
BU
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
BU
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
BU
Rallybio to Present at Upcoming Investor Conferences in November
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLYB Stock
  4. News Rallybio Corporation
  5. Press Releases